More drugs pass the NICE testBMJ 2000; 321 doi: https://doi.org/10.1136/bmj.321.7265.853/a (Published 07 October 2000) Cite this as: BMJ 2000;321:853
- Rhona MacDonald
A class of clot busting drugs, known as “super aspirin,” should be given to all high risk patients who have had a heart attack, despite the fact that it will cost the NHS more than £14m ($19.6m) a year, the National Institute for Clinical Excellence has ruled.
The institute published guidance last week saying that intravenous glycoprotein IIb/IIIa inhibitors should be given to all high risk patients who have had a minor heart attack, have unstable angina, or are undergoing balloon angioplasty.
These drugs are so named because they bind to factors IIa and IIIb in the clotting cascade and so prevent fibrinogen binding to …
Log in using your username and password
Log in through your institution
Sign up for a free trial